Could Carterra Inc.’s Vega HT-SPR accelerate fragment and small-molecule discovery without compromising rigor
Find out how Carterra Inc.’s Vega HT-SPR platform could redefine primary screening and reshape early drug discovery workflows.
Medical Devices & Diagnostics
Pharma & Biotech
What Biofrontera’s Phase 3 results mean for non-facial actinic keratosis treatment strategies
Biofrontera reports positive Phase 3 Ameluz data outside the face and scalp. Find out how this could change actinic keratosis treatment.
Pharma & Biotech
FDA removes CNS limitation for Yescarta, reshaping the regulatory boundary for CAR T therapy in primary CNS lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration to update the prescribing information for Yescarta axicabtagene ciloleucel by removing the prior limitation of use in patients with relapsed or refractory primary central nervous system lymphoma. The decision follows safety findings from an investigator sponsored Phase 1
Medical Devices & Diagnostics
TRUE METRIX labeling change puts focus on how glucose meters communicate extreme-risk events
Trividia Health, Inc. has initiated a labeling correction for all TRUE METRIX blood glucose monitoring systems to update how the E-5 error code is described in owner booklets and instructions for use across multiple international markets. The change clarifies that users experiencing symptoms of high blood glucose alongside an E-5 reading must seek immediate medical
Medical Devices & Diagnostics
Rapid Medical’s DISTALS trial signals a structural shift in how medium vessel stroke may finally be treated
Rapid Medical disclosed late-breaking results from its DISTALS randomized controlled trial showing that the TIGERTRIEVER 13 thrombectomy device achieved significantly higher tissue reperfusion without symptomatic intracranial hemorrhage compared with medical management in medium vessel occlusion stroke. The data were presented at the 2026 International Stroke Conference and form the basis for a planned United States
Medical Devices & Diagnostics
Johnson & Johnson’s early OMNYPULSE data show promise, but the real test lies ahead
Johnson & Johnson has presented 12-month pilot data from the OMNY-AF study evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation at the 2026 AF Symposium. The early pilot cohort reported high acute procedural success, no procedure-related adverse events, and a 12-month freedom from atrial fibrillation rate approaching 90 percent. The
Pharma & Biotech
Genentech’s fenebrutinib challenges the PPMS treatment ceiling but does not yet reset it
Genentech has reported late-breaking Phase III data from the FENtrepid trial showing that its investigational Bruton’s tyrosine kinase inhibitor fenebrutinib achieved non-inferiority to ocrelizumab in reducing disability progression in patients with primary progressive multiple sclerosis. The results were presented at the ACTRIMS Forum 2026 and position fenebrutinib as the first oral, brain-penetrant therapy to directly
Pharma & Biotech
What TG Therapeutics’ ACTRIMS strategy signals about the next competitive phase in anti-CD20 multiple sclerosis therapy
Find out how TG Therapeutics’ ACTRIMS strategy reshapes competition in anti-CD20 multiple sclerosis therapy and what clinicians and regulators are watching next.
Pharma & Biotech
Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program
Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.
Features & Analysis
Anathapindika Health expands retail footprint, testing detox-first nutraceutical demand in specialty stores
Discover what Anathapindika Health’s AlchePharma retail expansion signals for detox-focused nutraceuticals and the evolving wellness retail landscape.